Off-label

Off-label prescribing means a doctor prescribes an approved medication for a condition, dose, or group the FDA hasn’t specifically approved it for. It’s legal, common across all of medicine, and central to the GLP-1 story.

The GLP-1 examples

The same molecules are approved for different things under different brand names:

• Semaglutide: Ozempic is approved for type 2 diabetes; Wegovy is approved for weight management. Prescribing Ozempic specifically for weight loss is off-label — same drug, but the weight indication belongs to Wegovy.
• Tirzepatide: Mounjaro (diabetes) vs Zepbound (weight management and sleep apnea) work the same way.

So “Ozempic for weight loss,” which you’ll hear constantly, is technically off-label use — while Wegovy for the identical purpose is on-label.

Why the distinction matters practically

Clinically, off-label use is legitimate and widespread. Where it bites is insurance and cost:

• Insurers often won’t cover a drug used off-label, or require a heavier prior authorization.
• The on-label product for your actual goal (e.g. Wegovy for weight) is usually the cleaner coverage path — but availability, shortages, and price sometimes push prescribers and patients toward the off-label route anyway.

The takeaway

Off-label isn’t sketchy or unusual — it’s a normal tool of medical practice. But knowing whether your prescription is on- or off-label for your goal explains a lot of what happens next with coverage, and it’s a fair thing to ask your prescriber directly.